

		Clinical Trials			EMA/MHRA Approval	To Patients	
		Phase 1 (safety)	Phase 2 (efficacy)	Phase 3 (proof)			
SMN-dependent	antisense oligonucleotide (targeting <i>SMN2</i>)					█	
	Ionis/Biogen Spinraza/nusinersen		█				
	Ionis/Biogen Spinraza/nusinersen (High Dose)			Phase 3b Recruiting			
	Ionis/Biogen BIIB115		█				
	<i>SMN1</i> gene replacement						
	Novartis Gene Therapies/Novartis Zolgensma/onasemnogene abeparvovec (intravenous)		█				SMA Type 1 Only *
	Novartis Gene Therapies/Novartis Zolgensma/onasemnogene abeparvovec (intrathecal)		█				
	small molecule (targeting <i>SMN2</i>)						
	PTC/Roche Evrysdi/risdiplam (oral solution)		█				
	PTC/Roche Evrysdi/risdiplam (tablet form)		█				
Combination	combined treatments					█	
	Scholar Rock SRK-015/apitegromab	nusinersen or risdiplam	█				
	Biohaven Pharmaceuticals taldefgrobep alfa	nusinersen or risdiplam or onasem. abeparv.	█				
	Roche GYM329/RO7204239	PTC/Roche risdiplam	Phase 2/3 Recruiting				
SMN-independent	muscle-directed					█	
	NMD Pharma NMD670		SMA Type 3 Only *	█			

* Subject to country eligibility criteria